Mednax, Inc (MD) Shares Sold by Fmr LLC
Fmr LLC reduced its holdings in shares of Mednax, Inc (NYSE:MD) by 42.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,062,543 shares of the company’s stock after selling 2,251,038 shares during the quarter. Fmr LLC owned approximately 3.27% of Mednax worth $184,886,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of MD. BlackRock Inc. increased its holdings in shares of Mednax by 0.3% during the 2nd quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock worth $498,505,000 after acquiring an additional 28,155 shares during the last quarter. Vanguard Group Inc. raised its stake in Mednax by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after acquiring an additional 38,645 shares during the period. Longview Partners Guernsey LTD raised its stake in Mednax by 10.3% in the 2nd quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock valued at $303,267,000 after acquiring an additional 467,845 shares during the period. State Street Corp raised its stake in Mednax by 2.2% in the 1st quarter. State Street Corp now owns 2,943,797 shares of the company’s stock valued at $204,246,000 after acquiring an additional 62,812 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Mednax by 22.6% in the 2nd quarter. Victory Capital Management Inc. now owns 2,423,865 shares of the company’s stock valued at $146,329,000 after acquiring an additional 446,074 shares during the period.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is currently owned by corporate insiders.
MD has been the subject of a number of research analyst reports. BidaskClub cut shares of Mednax from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Robert W. Baird reissued a “hold” rating and issued a $47.00 price objective on shares of Mednax in a research report on Sunday, September 3rd. Jefferies Group LLC set a $46.00 price objective on shares of Mednax and gave the company a “hold” rating in a research report on Sunday, July 30th. Mizuho reissued a “neutral” rating and issued a $48.00 price objective (down from $62.00) on shares of Mednax in a research report on Tuesday, August 1st. Finally, KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price for the company in a research note on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the stock. Mednax currently has an average rating of “Hold” and an average price target of $58.89.
Shares of Mednax, Inc (NYSE:MD) opened at 44.80 on Wednesday. The stock has a 50 day moving average of $43.02 and a 200-day moving average of $54.41. The company has a market cap of $4.13 billion, a PE ratio of 14.27 and a beta of 0.37. Mednax, Inc has a 12 month low of $40.78 and a 12 month high of $72.13.
Mednax (NYSE:MD) last posted its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company had revenue of $843.00 million for the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the previous year, the firm posted $1.03 EPS. Mednax’s revenue was up 9.2% on a year-over-year basis. Equities analysts forecast that Mednax, Inc will post $3.31 earnings per share for the current year.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.